Registro de fonte primária
RelevantePedido submetido
PTC vai adquirir a terapia gênica ST-920 para Fabry; pedido de BLA previsto para o Q4 2026
PTC was selected as winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo. The company plans to complete a rolling BLA submission for accelerated approval in Q4 2026, leveraging existing rare-disease infrastructure. The acquisition remains subject to bankruptcy court approval and other closing conditions expected in late Q3 or early Q4 2026.
Fatos principais
- Arquivado
- 13 de ago. de 2026, 11:00
- Evento
- Pedido submetido
- Direção
- Positivo
- Empresa
PTCTPTC Therapeutics- Fonte
- SEC 8-K
- Confiança
- Com fonte
- Pagamento inicial
- $111 milhões
- Marcos
- Até $100 milhões
Trecho da fonte
EX-99.1 2 tmb-20260812xex99d1.htm EX-99.1 Exhibit 99.1 PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program – Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J., Aug. 12, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-tim
Mais sobre este ativo
Notável
28 de ago. de 2026
20:06
PTCTPTC TherapeuticsPTC Therapeutics adquire terapia génica AAV ST-920 para a doença de Fabry